FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1490-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1489-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 950 mcg/ml + Bupivacaine 5 mg/ml Intrathecal Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1488-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 8

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1487-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 7

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1486-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 4

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1485-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 3

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1484-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 20

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1483-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 15

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1482-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 100 mcg/ml +Clonidine 400 mcg/ml Intrathecal Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1481-2015

Class II · Moderate risk Terminated Jun 2, 2015

Fentanyl 10

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1480-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol Valerate 40 mg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1479-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol Valerate 20 mg/ml Injectable ml Multi-Dose Vial

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1478-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol Cypionate 5mg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1477-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 8 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1476-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 6 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1475-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 50 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1474-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 4 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1473-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 3 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1472-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 25 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1471-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 22 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1470-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 20 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1469-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 18 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1468-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 15 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1467-2015

Class II · Moderate risk Terminated Jun 2, 2015

Estradiol 12.5 mg

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1466-2015